ALPS Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $528K | Sell |
21,317
-1,715
| -7% | -$40.9K | ﹤0.01% | 723 |
|
|
2025
Q4 | $538K | Buy |
23,032
+200
| +0.9% | +$4.46K | ﹤0.01% | 701 |
|
|
2025
Q3 | $450K | Buy |
22,832
+6,154
| +37% | +$127K | ﹤0.01% | 801 |
|
|
2025
Q2 | $362K | Buy |
16,678
+202
| +1% | +$4.77K | ﹤0.01% | 846 |
|
|
2025
Q1 | $400K | Sell |
16,476
-633
| -4% | -$14.3K | ﹤0.01% | 622 |
|
|
2024
Q4 | $357K | Sell |
17,109
-400
| -2% | -$8.59K | ﹤0.01% | 775 |
|
|
2024
Q3 | $348K | Sell |
17,509
-3,960
| -18% | -$73.4K | ﹤0.01% | 879 |
|
|
2024
Q2 | $333K | Sell |
21,469
-83,246
| -79% | -$1.3M | ﹤0.01% | 781 |
|
|
2024
Q1 | $1.67M | Buy |
104,715
+32,284
| +45% | +$486K | 0.01% | 382 |
|
|
2023
Q4 | $1.22M | Sell |
72,431
-6,279
| -8% | -$85.8K | 0.01% | 422 |
|
|
2023
Q3 | $920K | Sell |
78,710
-20,884
| -21% | -$279K | 0.01% | 486 |
|
|
2023
Q2 | $1.34M | Buy |
99,594
+9,501
| +11% | +$137K | 0.01% | 399 |
|
|
2023
Q1 | $1.49M | Sell |
90,093
-1,013
| -1% | -$16.7K | 0.01% | 361 |
|
|
2022
Q4 | $1.69M | Buy |
91,106
+14,291
| +19% | +$220K | 0.02% | 332 |
|
|
2022
Q3 | $986K | Sell |
76,815
-29,943
| -28% | -$355K | 0.01% | 471 |
|
|
2022
Q2 | $748K | Sell |
106,758
-45,483
| -30% | -$334K | 0.01% | 518 |
|
|
2022
Q1 | $1.26M | Sell |
152,241
-42,253
| -22% | -$299K | 0.01% | 287 |
|
|
2021
Q4 | $1.32M | Sell |
194,494
-5,906
| -3% | -$38.8K | 0.01% | 328 |
|
|
2021
Q3 | $1.06M | Sell |
200,400
-17,478
| -8% | -$95.6K | 0.01% | 383 |
|
|
2021
Q2 | $1.25M | Sell |
217,878
-51,382
| -19% | -$265K | 0.01% | 378 |
|
|
2021
Q1 | $1.24M | Buy |
269,260
+4,258
| +2% | +$16.9K | 0.01% | 375 |
|
|
2020
Q4 | $885K | Buy |
265,002
+52,699
| +25% | +$177K | 0.01% | 399 |
|
|
2020
Q3 | $631K | Buy |
212,303
+71,223
| +50% | +$279K | 0.01% | 399 |
|
|
2020
Q2 | $652K | Sell |
141,080
-46,268
| -25% | -$208K | 0.01% | 409 |
|
|
2020
Q1 | $721K | Sell |
187,348
-21,842
| -10% | -$89.7K | 0.01% | 359 |
|
|
2019
Q4 | $784K | Buy |
+209,190
| New | +$978K | 0.01% | 397 |
|
|
2019
Q2 | – | Sell |
-248,154
| Closed | -$1.27M | – | 884 |
|
|
2019
Q1 | $1.27M | Buy |
248,154
+10,715
| +5% | +$31.5K | 0.01% | 281 |
|
|
2018
Q4 | $456K | Buy |
237,439
+55,884
| +31% | +$160K | ﹤0.01% | 506 |
|
|
2018
Q3 | $686K | Buy |
181,555
+32,661
| +22% | +$102K | ﹤0.01% | 480 |
|
|
2018
Q2 | $465K | Buy |
148,894
+11,453
| +8% | +$34.7K | ﹤0.01% | 657 |
|
|
2018
Q1 | $328K | Buy |
137,441
+26,262
| +24% | +$87.3K | ﹤0.01% | 806 |
|
|
2017
Q4 | $435K | Buy |
+111,179
| New | +$367K | ﹤0.01% | 662 |
|
Other funds holding CPRX
VCM
DM
VPM
ALPS Advisors's CPRX Position: Q1 2026 in Review
ALPS Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 7.4% in Q1 2026, selling an estimated $40.9K and leaving 21,317 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #723.
ALPS Advisors first reported a position in CPRX in Q4 2017 and has held it in 32 quarters since. The position peaked at $1.69M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- ALPS Advisors held 21,317 shares of Catalyst Pharmaceutical worth $528K as of Q1 2026.
- ALPS Advisors sold 1,715 Catalyst Pharmaceutical shares in Q1 2026, an estimated $40.9K.
- Catalyst Pharmaceutical made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #723 holding.
- ALPS Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 32 quarters since.
- ALPS Advisors's Catalyst Pharmaceutical position peaked at $1.69M in Q4 2022.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.